LHCQX Mutual Fund

NAV$22.70

Fund Essentials - as of Apr 30, 2026

Net Assets
-
Expense Ratio
1.28%
Dividend Yield (Current)
-
Holdings
64
Inception Date
Jul 31, 2019
Fund Family
Lord Abbett Family of Funds
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Unspecified

Performance

YTD+4.47%
1 Year+26.96%
3 Year+8.83%
5 Year+5.38%

Asset Allocation

Stocks: 96.38%
Cash: 1.69%
Other: 1.93%

Price Chart (6M)

Loading chart data...

Top Holdings

View All →
TickerNameWeight
LLYEli Lilly & Co8.89%
AZN:LNAstraZeneca PLC4.73%
GILDGilead Sciences Inc4.25%
JNJJohnson & Johnson3.19%
NKTRNektar Therapeutics3.17%
Top 10 Concentration: 37.55%Report Date: Apr 30, 2026
Download all 64 holdings for LHCQX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Frequency
Unspecified
Latest Distribution
$1.47
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO
See how LHCQX ranks against its peers
Category rank, peer-average returns and outperformance, updated daily.
$49$29/mo
Claim the $29 launch price
First 500 subscribers, then $49/mo. Cancel anytime. From MarketXLS, trusted since 2014.

LHCQX Mutual Fund Overview

LHCQX Mutual Fund (Lord Abbett Health Care Fund Class R3) is managed by Lord Abbett Family of Funds. LHCQX expense ratio is 1.28%, holding 64 positions across sectors including Health Care, Unknown, Other. Inception date: 2019-07-31.

LHCQX performance shows a YTD return of 4.47%. The 1-year return is 26.96% and the 5-year return is 5.38%.

LHCQX top holdings include Eli Lilly & Co (8.9%), AstraZeneca PLC (4.7%), Gilead Sciences Inc (4.3%), Johnson & Johnson (3.2%), Nektar Therapeutics (3.2%). View all LHCQX holdings, sector breakdown, or dividend history.

LHCQX can be compared against other funds using the overlap calculator or side-by-side comparison tool. LHCQX alternatives are available via the screener, along with tax-loss harvesting opportunities.